Protalix BioTherapeutics Inc. has released a corporate presentation highlighting its established commercial foundation and ongoing expansion into the rare disease space. The presentation details the commercialization of Elfabrio® (pegunigalsidase alfa-iwxj), a product approved for the treatment of adult patients with Fabry disease. The document discusses various aspects of Elfabrio, including its revenue, expenses, market acceptance, competition, and regulatory considerations. The presentation also touches upon the regulatory approval and commercial prospects of other products and product candidates within the company's portfolio. You can access the full presentation through the link below.